‘Ozempic face' may be driving cosmetic surgery boom
Plastic Surgeon Dr. Bob Basu on if 'Ozempic face' is a real concern and why are user seeing side-effects after weight loss.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
2 hours ago
- Globe and Mail
Why UnitedHealth Stock Dipped Today After Bumping Higher Monday
Key Points One pundit tracking the stock became less bullish on its future. He knocked down his price target by 37%. 10 stocks we like better than UnitedHealth Group › What the stock analysis community giveth, it can also taketh away. That was the dynamic behind the slide of UnitedHealth Group (NYSE: UNH) stock on Tuesday. As in the previous trading session, the big insurer was affected by an analyst's price target move. This time, however, this took the form of a cut rather than a raise. UnitedHealth closed the day down by 1.5% in value, a worse showing than the S&P 500 's (SNPINDEX: ^GSPC) 0.6% decrease. A chop from a bull The analyst behind the slice was Lance Wilkes from Bernstein SocGen Group. Well before the market open Tuesday, Wilkes took a powerful weed whacker to his UnitedHealth fair value assessment, reducing it to $377 per share; formerly, he believed it was worth as much as $594. Despite the rather drastic adjustment, he maintained his recommendation of outperform (buy, in other words). According to reports, Wilkes wrote in his UnitedHealth update that he expects the company's performance to remain weak through this year, and has commensurately reduced his earnings estimate and target P/E. For the former, he cut his per-share profitability for full-year 2026 by 13%, and for the latter to 12.5 from the preceding 18. The analyst also cited sluggish growth in the insurer's key OptumHealth unit as a reason for his price target cut. Warren likes it UnitedHealth has landed on many an investor's radar following news last week that Berkshire Hathaway had plonked down $1.6 billion for a stake in the company. Anytime Warren Buffett 's investment vehicle buys (or sells, for that matter) a pack of stock for its equity portfolio, the target company becomes a lightning rod for investors. Buffett and Berkshire surely see a company that has potential to reach. Others might consider it something of a clunky underperformer that's fairly -- or even overly -- valued these days. Should you invest $1,000 in UnitedHealth Group right now? Before you buy stock in UnitedHealth Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and UnitedHealth Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $671,466!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,115,633!* Now, it's worth noting Stock Advisor's total average return is 1,077% — a market-crushing outperformance compared to 185% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 18, 2025
CBC
3 hours ago
- CBC
Ozempic approved in Canada to slow kidney decline, prevent cardiovascular disease
Social Sharing Health Canada has approved Ozempic to reduce the risk of further kidney decline among patients with Type 2 diabetes. Between 30 and 50 per cent of people with Type 2 diabetes develop some form of chronic kidney disease. An international clinical trial, called FLOW, showed the risk of kidneys significantly deteriorating or failing was 24 per cent lower in patients taking Ozempic compared to those taking a placebo injection. The patients taking the drug were also less likely to die from cardiovascular disease — another condition that affects many patients with diabetes. The study, funded by Ozempic manufacturer Novo Nordisk, was peer-reviewed and published in the New England Journal of Medicine last year and contributed to Health Canada's decision. Avoiding dialysis Dr. David Cherney, a nephrologist at Toronto General Hospital, helped lead the Canadian part of the trial and says the results show it's possible to reduce the loss of kidney function before patients need dialysis or a kidney transplant. "What my patients are scared of is dialysis — dialysis or a transplant," said Cherney, who is also a senior scientist at the Toronto General Hospital Research Institute, in an interview. "I can reasonably reduce that risk and thereby reduce their anxiety and fear of serious, serious complications. Not to mention all the cardiovascular disease, which patients are also extremely afraid of." WATCH | Retinal disease tied to Ozempic and Mounjaro use in people with diabetes: Ozempic, Mounjaro linked to vision loss in diabetics 2 months ago Researchers at the University of Toronto have found GLP-1 weight loss and diabetes drugs like Ozempic and Mounjaro double the risk of a severe form of vision loss among diabetics, affecting daily activities such as reading and driving. Dr. Ehud Ur, an endocrinologist in Vancouver who was not involved in the study, said the results are credible and that Health Canada's approval of Ozempic to help prevent kidney decline is "great news." "The prevention of kidney disease is a very important goal in the management of patients with Type 2 diabetes and this is another tool," said Ur, who is a professor of endocrinology and metabolism at the University of British Columbia. Ozempic is the brand name of an injectable dose of semaglutide, a glucagon-like peptide-1 (GLP-1) hormone. Ozempic was first approved in Canada as a diabetes medication in 2018 because it reduces blood sugar. Semaglutide can also decrease appetite. In 2021, Health Canada approved it as a weight-loss drug for people with obesity at a higher dose sold by Novo Nordisk under the brand name Wegovy. Following global supply shortages, in January 2025 Health Canada said the supply of Ozempic and other GLP-1 receptor agonists had stabilized. Heart protection benefits established In an email to The Canadian Press, Health Canada confirmed that on Aug. 13, it had approved Ozempic "to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease and cardiovascular death in adults with Type 2 diabetes and chronic kidney disease." Glomerular filtration rate is a measure that shows how well the kidneys are filtering out waste and excess water. Ozempic is the first GLP-1 drug approved in Canada to protect both kidneys and the heart in patients with Type 2 diabetes, said Ur, noting that the cardiovascular benefits of semaglutide have been extensively studied. "The benefit of Ozempic is that you also get weight loss, which is a very important goal for most people [with Type 2 diabetes]. That's a very exciting combination," he said. Some people experience gastrointestinal side effects when they take Ozempic, Ur said, including nausea, vomiting, constipation and diarrhea. More severe complications can include gall bladder inflammation and pancreatitis but most side effects are minor, he said. The benefit of slowing or stopping progressive kidney disease in people with diabetes would outweigh the risks of minor side effects, Ur said.
Globe and Mail
4 hours ago
- Globe and Mail
OnlineMed launches its Online Service, providing instant Access to Instant Doctor's Notes Online
OnlineMed introduced an online service to allow doctors to write absent notes without physically visiting schools or workplaces. OnlineMed has officially been launched and is set to change the way Americans can access virtual doctor's notes. This idea will address the hectic visits to the doctor's clinic, even when the world is moving fast and working with technology. The entire process of getting a note written by a doctor for being absent finally has a convenient and smooth way, making people's lives easier. People can finally avoid the long waiting hours and the additional medical fees. Workplaces and schools always demand a legitimate doctor's note for being absent, and people always hated visiting the clinic for this trivial task, and for the longest time, no one ever thought of bringing a solution to this. However, OnlineMed understood the need at the right time and, by utilizing the latest technology, they are enabling people to access these notes from the comfort of their homes. They will be provided with these notes in a matter of a few hours. The process of accessing a genuine doctor's note has been kept extremely easy. People simply have to go to the website and request a doctor's written note. This process eliminates the compulsion of being physically present at the clinic for a simple task that requires a minimum amount. OnlineMed understood this need of the majority right at the time and has introduced this service at $39. At the time of launch, the founder, Justin Garner, said, 'I have been through the hectic process of getting a doctor's note many times. It not only costed me money but also my time, which I could have utilized better. This website addresses this issue very well, and even if it takes a couple of hours to provide the note, you can still stay at your home and not wait in the waiting rooms.' OnlineMed not only provides you with online medical note service, but also ensures that the doctors they are working with are legitimate and hold a degree. Before issuing you the note, every request goes through review and then only gets issued by a licensed provider, making the notes legit and accurate. The task of developing OnlineMed was started back in October 2024 and finally took its shape now. Though this will help everyone to get the doctor's appointment right on time and at a very convenient cost, it will especially come as a relief to those who work for hourly gigs, full-time parents, and working multiple jobs. Those who had to travel a long distance will also find this very useful. The launch of OnlineMed will put people at ease, and the services may be utilized for bigger and better causes. In the time when online services are making things easier, the traditional method did feel like a burden, but not anymore. The website is now live, and anyone can request the doctor's written note. Media Contact Company Name: OnlineMed Contact Person: Justin Garner Email: Send Email City: Sheridan State: WY Country: United States Website:
